Generic Pharmaceuticals
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global generic pharmaceutical market insights. Stay ahead with regulatory updates, competitive intelligence, and strategic analysis for BD and investment.
Showing 1–12 of 16 articles
Quick answer
NovaPharmaNews Generic Pharmaceuticals hub for FDA covers 16 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Amneal Romidepsin FDA Approval: B2B Analysis for BD Teams and Investors
Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data
Supreme Court sides with generic drug maker in icosapent ethyl patent case
Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
FDA Approves Oral Nilotinib Tablets for Ph+ CML: A New Era for Treatment
Sun Pharma and Organon File HSR, Awaiting Antitrust Clearance
Cumberland Pharmaceuticals (NASDAQ: CPIX) to divest marketed brands to Apotex for $100M
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market
Accord Healthcare Relaunches Tadalafil Tablets in Multiple Dosage Strengths, Expanding Generic ED Treatment Access
Phathom Pharmaceuticals VOQUEZNA Sales Surge 104% in Q1 2026, Company Maintains Profitability Guidance
FDA Generic Drug User Fee Amendments (GDUFA) Program Updates Fee Structure and Payment Methods for 2024
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.